Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Gaoting, Mo Ran, Zuo Yingting, Ma Qingfeng, Zhao Guangjian, Yao Xiaoxi, Liang Ji, Zhou Li, He Yong, Long Faqing, Yuan Zhengzhou, Liu Lei, Han Guosheng, Tan Yan, Ai Zhibing, Cai Chunsheng, Liu Juan, Zhang Liyong, Yang Haihua, Yi Tingyu, Li Li, Fu Yao, Zhang Yanxing, Shao Xiangzhong, Yu Zhipeng, Wu Saizhen, Du Yanqiu, Mao Lingqun, Guo Hongling, Chen Xufeng, Chen Yifei, Zhao Qiong, Chi Liyi, Liu Yi, Zhang Haochun, Li Guangzong, Meng Shujuan, Wu Yifan, Wu Jieying, Jiang Ziying, Lei Shaoyuan, Gao Daiquan, Zhong Lianmei, Fiehler Jens, Wang Duolao, Nguyen Thanh N, Saver Jeffrey L, Hao Junwei, OPTION Investigators
Аннотация
OBJECTIVE: To assess the efficacy and safety of intravenous tenecteplase administered 4.5 to 24 hours after stroke onset in patients with non-large vessel occlusion and salvageable brain tissue.
DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, blinded end-point clinical trial was conducted at 48 centers in China. A total of 566 patients with non-large vessel occlusion stroke and evidence of potentially salvageable tissue determined on perfusion imaging presenting within 4.5 to 24 hours of the time last seen well were recruited between June 2, 2023, and August 4, 2025 (final follow-up, October 28, 2025).
INTERVENTIONS: Patients were randomly assigned 1:1 using a minimization algorithm to receive intravenous tenecteplase (0.25 mg/kg; maximum dose, 25 mg; n = 282) or standard medical treatment (n = 284).
MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin Scale at 90 days. Safety outcomes included symptomatic intracranial hemorrhage within 36 hours and mortality within 90 days.
RESULTS: Among the 570 patients randomized, 566 were included in the primary analysis (median age, 68 [IQR, 59-75] years; 196 female [34.6%]). An excellent functional outcome was observed in 123 of 282 patients (43.6%) in the tenecteplase group and 97 of 284 (34.2%) in the control group (risk ratio, 1.28 [95% CI, 1.04-1.57]; P = .02). The incidence of symptomatic intracranial hemorrhage at 2.8% was higher with tenecteplase than with standard medical treatment at 0% (risk difference, 2.85% [95% CI, 1.16%-5.54%]; P = .004), and the mortality at 90 days was 5.0% and 3.2%, respectively (risk ratio, 1.57 [95% CI, 0.69-3.57]; P = .28).
CONCLUSIONS AND RELEVANCE: Among patients with non-large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase administered 4.5 to 24 hours after onset resulted in a greater likelihood of an excellent functional outcome at 90 days than standard care but had an increased risk of symptomatic intracranial hemorrhage.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05752916.